Custom Search


Saturday 01 April 2006

Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.

By: Lim SW, Gillis D, Smith W, Hissaria P, Greville H, Peh CA.

Intern Med J 2006 Apr;36(4):260-2

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.

Use of this site is subject to the following terms of use